Track topics on Twitter Track topics that are important to you
Just over one year ago, the Hong Kong Stock Exchange announced its brand new IPO pathway for "pre-revenue" China biopharmas. Since then, seven biopharmas have completed IPOs under the new rules, and the results tell a tale of two quite different markets: the first three lost money for their IPO investors while the last four generated very attractive returns -- three of the last four are now more than 65% higher than their IPO prices. It isn't really two different markets; it only seems that way. We look into what changed. [Editor's Note: A panel on Capital Markets at the ChinaBio Partnering Forum in Shanghai on May 8-9 will feature some of these companies as panelists.] More details....
Original Article: Hong Kong's Pre-Revenue China Biotech IPOs: A Tale of Two MarketsNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...